Black Diamond Therapeutics, Inc. (BDTX)

Compare

1.4900

-0.0600

(-3.87%)

At close: 4:00:02 PM EDT

1.5000

+0.01

+(0.67%)

After hours: 4:45:06 PM EDT

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced its participation in upcoming investor conferences. Presentation details with President and Chief Executive Officer, Mark Velleca, M.D., Ph.D., are as follows: 24th Annual Needham Virtual Healthcare Conference presentation at 3:00pm ET on Monday, A

GlobeNewswire yesterday

BDTX
-3.87%
Servier and Black Diamond sign deal for solid tumours therapy

Servier will be responsible for development and global commercialisation of the therapy for several indications.

Pharmaceutical Technology 12 days ago

BDTX
-3.87%
Top Midday Gainers

Black Diamond Therapeutics (BDTX) and French pharmaceutical group Servier said Wednesday that they h

PREMIUM
MT Newswires 13 days ago

BDTX
-3.87%
BA
Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy

The partnership underscores Servier’s commitment to developing targeted therapies that address unmet medical needs in oncologyServier will develop and commercialize BDTX-4933, a Phase 1 asset with best-in-class potential targeting both RAS mutations and RAF alterations, in solid tumors, including non-small cell lung cancerBlack Diamond will receive an upfront payment of $70 million and up to $710 million in development and commercial sales milestone payments plus royalties SURESNES, France and C

GlobeNewswire 13 days ago

BDTX
-3.87%
Black Diamond: Q4 Earnings Snapshot

CAMBRIDGE, Mass. AP) — Black Diamond Therapeutics, Inc. BDTX) on Thursday reported a loss of $16 million in its fourth quarter.

Associated Press Finance 25 days ago

BDTX
-3.87%
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Clinical data on track for Q2 2025 in Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLCExpansion of investigator sponsored “window of opportunity” trial into newly diagnosed glioblastoma patients with EGFR aberrations expected in Q1 2025Cash, cash equivalents, and investments of $98.6 million as of December 31, 2024, expected to be sufficient to fund operations into Q4 2026 CAMBRIDGE, Mass., March 06, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX)

GlobeNewswire 25 days ago

BDTX
-3.87%
NAYA Biosciences Announces Nomination of New Board Members

New board reflects company’s added focus on oncology & autoimmune diseases SARASOTA, Fla. and MIAMI, Feb. 19, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women’s health, today announced that its board of directors has nominated five new candidates with extensive experience in in the biotechnology industry to be approved at the company shareholder

GlobeNewswire last month

NAYA

KYMR

BDTX
-3.87%
February 2025 US Penny Stocks With Promising Prospects

As of February 2025, the U.S. stock market is showing signs of strength, with major indexes like the S&P 500 closing just shy of record highs and posting weekly gains. In such a robust market environment, investors often seek opportunities in lesser-known corners like penny stocks. These smaller or newer companies can offer significant growth potential when supported by strong financial fundamentals. We'll explore three penny stocks that stand out for their financial resilience and potential...

Simply Wall St. last month

BDTX
-3.87%
BRCC

GNTA
3 US Penny Stocks With Market Caps Under $200M

As the U.S. stock market navigates a period of mixed performance, with tech stocks under pressure and bond yields on the rise, investors are looking for opportunities beyond the major indices. For those willing to explore smaller or newer companies, penny stocks—despite their somewhat outdated name—continue to offer intriguing possibilities. These stocks often represent affordability and growth potential, particularly when backed by solid financials.

Simply Wall St. 2 months ago

BDTX
-3.87%
SOPH

NVRO
Raymond James Predicts Up to ~930% Rally for These 2 ‘Strong Buy’ Stocks

The S&P 500 wrapped up the first full week of 2025 on a sour note, as December’s labor market data surprised to the upside. U.S. employers added 256,000 jobs last month, significantly outpacing economists’ forecast of 155,000. Meanwhile, the unemployment rate dropped to 4.1%, better than the anticipated 4.2%. This robust jobs report underscores the continued strength of the U.S. labor market and the broader economy. However, while this resilience is encouraging, it also raises concerns that the

TipRanks 2 months ago

INMB

BDTX
-3.87%
US Penny Stocks Spotlight: Information Services Group Among 3 Top Picks

As the U.S. stock market experiences a pullback from its recent highs, investors are keeping a close eye on economic indicators and Federal Reserve actions that could influence future trends. In this context, penny stocks—though an older term—remain relevant as they often represent smaller or emerging companies with potential for growth. By focusing on those with strong financials and clear growth prospects, investors can uncover opportunities in this unique segment of the market.

Simply Wall St. 3 months ago

BDTX
-3.87%
NAUT

III
Black Diamond: Q3 Earnings Snapshot

CAMBRIDGE, Mass. AP) — Black Diamond Therapeutics, Inc. BDTX) on Tuesday reported a loss of $15.6 million in its third quarter.

Associated Press Finance 4 months ago

BDTX
-3.87%
Vanda Pharmaceuticals Leads The Pack Of 3 US Penny Stocks

As the U.S. stock market navigates the complexities of a presidential election and anticipated Federal Reserve rate decisions, investors are closely watching the movements of major indices like the Dow Jones and Nasdaq. In such a climate, penny stocks—though an older term—remain relevant for those seeking investment opportunities in smaller or newer companies. These stocks often offer potential value when supported by strong financials, presenting a unique opportunity for growth at lower...

Simply Wall St. 4 months ago

KLTR

VNDA

BDTX
-3.87%
Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Announced encouraging initial Phase 2 data of BDTX-1535 in patients with recurrent EGFRm NSCLC with a broad spectrum of classical, non-classical, and C797S resistance mutations in September 2024 Presented real-world treatment practices and patient outcomes in newly diagnosed NSCLC patients with non-classical EGFR mutations at the 2024 ESMO Congress Clinical updates of BDTX-1535 in EGFRm NSCLC and regulatory feedback expected in Q1 2025Cash, cash equivalents, and investments of $112.7 million as

GlobeNewswire 4 months ago

BDTX
-3.87%
Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway

Company advancing BDTX-1535 in EGFRm NSCLC towards key inflection points in Q1 2025 Will deprioritize BDTX-4933 and seek potential partners Anticipated cost savings expected to extend cash runway into Q2 2026 CAMBRIDGE, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, announced today a corporate restructuring to focus resou

GlobeNewswire 5 months ago

BDTX
-3.87%
Black Diamond Therapeutics' Lead Drug Candidate Shows Initial Anti-tumor Activity In Certain Type Of Lung Cancer Resistant To AstraZeneca's Drug

Monday, Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) reported initial Phase 2 data of BDTX-1535. The data demonstrated encouraging clinical responses and durability of BDTX-1535 in patients with relapsed/refractory epidermal growth factor receptor (EGFR)-mutant (EGFRm) non-small cell lung cancer (NSCLC). “Patients often become resistant to osimertinib with the emergence of on-target resistance EGFR mutations,” said Sergey Yurasov, Chief Medical Officer of Black Diamond Therapeutics. “Our preli

Benzinga 6 months ago

BDTX
-3.87%
AZN
Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations

BDTX-1535 dose of 200 mg daily selected for pivotal development; favorable tolerability profile and no new safety signals observed Preliminary ORR of 42% in 19 patients at 200 mg with on-target resistance EGFR mutations Encouraging durability with DOR of approximately 8 months or more for first 3 patients with a PR; 14 of 19 patients remain on treatment Regulatory feedback on registration path anticipated in Q1 2025 Initial results of BDTX-1535 in first-line NSCLC patients with non-classical EGF

GlobeNewswire 6 months ago

BDTX
-3.87%
Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC

Webcast to be held Monday, September 23, at 8:00 a.m. ET CAMBRIDGE, Mass., Sept. 22, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, will host a webcast to disclose initial phase 2 clinical trial results for BDTX-1535 in patients with recurrent EGFRm NSCLC on Monday, September 23, 2024, at 8:00am ET. Webcast information The webcast can be

GlobeNewswire 6 months ago

BDTX
-3.87%
Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024

Treatment data were analyzed from 3,276 cases of patients with newly diagnosed EGFR mutant NSCLC from Guardant Health Analyses of patients with non-classical EGFR mutations reveal that the majority receive frontline chemotherapy and the remainder are treated with osimertinib or afatinib Short time to treatment discontinuation ranging from four to eight months demonstrates clear unmet need for patients with non-classical EGFR mutant NSCLC CAMBRIDGE, Mass., Sept. 14, 2024 (GLOBE NEWSWIRE) -- Black

GlobeNewswire 6 months ago

BDTX
-3.87%
Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors

SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced the appointment of David M. Epstein, Ph.D., to Gyre’s Board of Directors (the “Board”), effective August 6, 2024. Dr. Epstein will serve as a member of the Audit Committee of the Board and as member of the Compensation Committee of the Board. “We are th

GlobeNewswire 7 months ago

BDTX
-3.87%
GYRE

Performance Overview

Return	BDTX	S&P 500 (^GSPC)
YTD	-30.37%	-4.23%
1-Year	-69.78%	+7.42%
3-Year	-45.82%	+23.92%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Black Diamond Therapeutics, Inc. (BDTX)

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

Servier and Black Diamond sign deal for solid tumours therapy

Top Midday Gainers

Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy

Black Diamond: Q4 Earnings Snapshot

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

NAYA Biosciences Announces Nomination of New Board Members

February 2025 US Penny Stocks With Promising Prospects

3 US Penny Stocks With Market Caps Under $200M

Raymond James Predicts Up to ~930% Rally for These 2 ‘Strong Buy’ Stocks

US Penny Stocks Spotlight: Information Services Group Among 3 Top Picks

Black Diamond: Q3 Earnings Snapshot

Vanda Pharmaceuticals Leads The Pack Of 3 US Penny Stocks

Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway

Black Diamond Therapeutics' Lead Drug Candidate Shows Initial Anti-tumor Activity In Certain Type Of Lung Cancer Resistant To AstraZeneca's Drug

Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations

Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC

Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024

Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors

Performance Overview